Cargando…
Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases
In recent years, numerous studies have shown that conversion of conventional drugs in ionic liquid (IL) formulation could be a successful strategy to improve their physicochemical properties or suggest a new route of administration. We report the synthesis and detailed characterization of eight sali...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746858/ https://www.ncbi.nlm.nih.gov/pubmed/35011452 http://dx.doi.org/10.3390/molecules27010216 |
_version_ | 1784630691343892480 |
---|---|
author | Klebeko, Joanna Ossowicz-Rupniewska, Paula Świątek, Ewelina Szachnowska, Joanna Janus, Ewa Taneva, Stefka G. Krachmarova, Elena Guncheva, Maya |
author_facet | Klebeko, Joanna Ossowicz-Rupniewska, Paula Świątek, Ewelina Szachnowska, Joanna Janus, Ewa Taneva, Stefka G. Krachmarova, Elena Guncheva, Maya |
author_sort | Klebeko, Joanna |
collection | PubMed |
description | In recent years, numerous studies have shown that conversion of conventional drugs in ionic liquid (IL) formulation could be a successful strategy to improve their physicochemical properties or suggest a new route of administration. We report the synthesis and detailed characterization of eight salicylic acid-based ILs (SA-ILs) containing cation non-polar or aromatic amino acid esters. Using in vitro assays, we preliminary evaluated the therapeutic potency of the novel SA-ILs. We observed that conversion of the SA into ionic liquids led to a decrease in its cytotoxicity toward NIH/3T3 murine embryo fibroblasts and human HaCaT keratinocytes. It should be mentioned is that all amino acid alkyl ester salicylates [AAOR][SA] inhibit the production of the proinflammatory cytokine IL-6 in LPS-stimulated keratinocytes. Moreover, keratinocytes, pretreated with [PheOMe][SA] and [PheOPr][SA] seem to be protected from LPS-induced inflammation. Finally, the novel compounds exhibit a similar binding affinity to bovine serum albumin (BSA) as the parent SA, suggesting a similar pharmacokinetic profile. These preliminary results indicate that SA-ILs, especially those with [PheOMe], [PheOPr], and [ValOiPr] cation, have the potential to be further investigated as novel topical agents for chronic skin diseases such as psoriasis and acne vulgaris. |
format | Online Article Text |
id | pubmed-8746858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87468582022-01-11 Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases Klebeko, Joanna Ossowicz-Rupniewska, Paula Świątek, Ewelina Szachnowska, Joanna Janus, Ewa Taneva, Stefka G. Krachmarova, Elena Guncheva, Maya Molecules Article In recent years, numerous studies have shown that conversion of conventional drugs in ionic liquid (IL) formulation could be a successful strategy to improve their physicochemical properties or suggest a new route of administration. We report the synthesis and detailed characterization of eight salicylic acid-based ILs (SA-ILs) containing cation non-polar or aromatic amino acid esters. Using in vitro assays, we preliminary evaluated the therapeutic potency of the novel SA-ILs. We observed that conversion of the SA into ionic liquids led to a decrease in its cytotoxicity toward NIH/3T3 murine embryo fibroblasts and human HaCaT keratinocytes. It should be mentioned is that all amino acid alkyl ester salicylates [AAOR][SA] inhibit the production of the proinflammatory cytokine IL-6 in LPS-stimulated keratinocytes. Moreover, keratinocytes, pretreated with [PheOMe][SA] and [PheOPr][SA] seem to be protected from LPS-induced inflammation. Finally, the novel compounds exhibit a similar binding affinity to bovine serum albumin (BSA) as the parent SA, suggesting a similar pharmacokinetic profile. These preliminary results indicate that SA-ILs, especially those with [PheOMe], [PheOPr], and [ValOiPr] cation, have the potential to be further investigated as novel topical agents for chronic skin diseases such as psoriasis and acne vulgaris. MDPI 2021-12-30 /pmc/articles/PMC8746858/ /pubmed/35011452 http://dx.doi.org/10.3390/molecules27010216 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Klebeko, Joanna Ossowicz-Rupniewska, Paula Świątek, Ewelina Szachnowska, Joanna Janus, Ewa Taneva, Stefka G. Krachmarova, Elena Guncheva, Maya Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases |
title | Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases |
title_full | Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases |
title_fullStr | Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases |
title_full_unstemmed | Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases |
title_short | Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases |
title_sort | salicylic acid as ionic liquid formulation may have enhanced potency to treat some chronic skin diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746858/ https://www.ncbi.nlm.nih.gov/pubmed/35011452 http://dx.doi.org/10.3390/molecules27010216 |
work_keys_str_mv | AT klebekojoanna salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases AT ossowiczrupniewskapaula salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases AT swiatekewelina salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases AT szachnowskajoanna salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases AT janusewa salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases AT tanevastefkag salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases AT krachmarovaelena salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases AT gunchevamaya salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases |